blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3124018

EP3124018 - ORAL FORMULATIONS OF DEFERASIROX [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  22.03.2024
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  17.11.2017
FormerGrant of patent is intended
Status updated on  12.10.2017
FormerExamination is in progress
Status updated on  10.03.2017
FormerRequest for examination was made
Status updated on  30.12.2016
Most recent event   Tooltip31.01.2025Lapse of the patent in a contracting state
New state(s): HR, IE, SK		published on 05.03.2025  [2025/10]
Applicant(s)For all designated states
NOVARTIS AG
Lichtstrasse 35
4056 Basel / CH
[2024/17]
Former [2017/05]For all designated states
NOVARTIS AG
Lichtstrasse 35
4056 Basel / CH
Inventor(s)01 / GHOSH, Indrajit
c/o Novartis Pharmaceuticals Corporation One
Health Plaza
East Hanover, New Jersey 07936-1080 / US
02 / ZHANG, Jia-Ai
c/o Novartis Pharmaceuticals Corporation One
Health Plaza
East Hanover, New Jersey 07936-1080 / US
 [2017/05]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2024/17]
Former [2017/05]Lardans, Vinca Raymonde
Novartis Pharma AG Patent Department
4002 Basel / CH
Application number, filing date16188627.006.03.2014
[2017/05]
Priority number, dateUS201361774893P08.03.2013         Original published format: US 201361774893 P
US201361824435P17.05.2013         Original published format: US 201361824435 P
[2017/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3124018
Date:01.02.2017
Language:EN
[2017/05]
Type: B1 Patent specification 
No.:EP3124018
Date:20.12.2017
Language:EN
[2017/51]
Type: B2 New European patent specification 
No.:EP3124018
Date:24.04.2024
Language:EN
[2024/17]
Search report(s)(Supplementary) European search report - dispatched on:EP05.12.2016
ClassificationIPC:A61K9/20, A61K9/28, A61K31/4196, A61P39/04
[2017/05]
CPC:
A61K9/2846 (EP,IL,KR,MX,US); A61K9/2077 (EP,IL,KR,MX,US); A61K31/4196 (EP,IL,KR,MX,US);
A61K31/125 (EP,US); A61K9/0053 (IL,US); A61K9/148 (US);
A61K9/2013 (IL,US); A61K9/2027 (IL,US); A61K9/2031 (EP,IL,KR,MX,US);
A61K9/2054 (EP,IL,KR,MX,US); A61K9/2095 (IL,KR,MX,US); A61K9/2886 (KR,MX,US);
A61K9/2893 (IL,KR,MX,US); A61K9/5026 (EP,IL,KR,MX,US); A61K9/5089 (IL,KR,MX,US);
A61P3/12 (EP,IL); A61P39/00 (EP); A61P39/04 (EP,IL);
A61P7/00 (EP,IL) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/05]
Extension statesBA13.09.2016
ME13.09.2016
TitleGerman:ORALE FORMULIERUNGEN VON DEFERASIROX[2017/05]
English:ORAL FORMULATIONS OF DEFERASIROX[2017/05]
French:FORMULATIONS ORALES DE DÉFÉRASIROX[2017/05]
Examination procedure13.09.2016Examination requested  [2017/05]
13.09.2016Date on which the examining division has become responsible
07.03.2017Despatch of a communication from the examining division (Time limit: M04)
24.03.2017Reply to a communication from the examining division
02.06.2017Despatch of a communication from the examining division (Time limit: M04)
11.09.2017Reply to a communication from the examining division
13.10.2017Communication of intention to grant the patent
06.11.2017Fee for grant paid
06.11.2017Fee for publishing/printing paid
06.11.2017Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14710654.6  / EP2964202
Opposition(s)Opponent(s)01  20.09.2018  27.09.2018  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
Opponent's representative
HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
 02  20.09.2018  27.09.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 [N/P]
Former [2021/48]
Opponent(s)01  20.09.2018  27.09.2018  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
Opponent's representative
HGF
1 City Walk
Leeds LS11 9DX / GB
 02  20.09.2018  27.09.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
Former [2020/51]
Opponent(s)01  20.09.2018  27.09.2018  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
Opponent's representative
HGF
1 City Walk
Leeds LS11 9DX / GB
 02  20.09.2018  27.09.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
Former [2020/30]
Opponent(s)01  20.09.2018  27.09.2018  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
Opponent's representative
HGF
1 City Walk
Leeds LS11 9DX / GB
 02  20.09.2018  27.09.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Schiener, Jens
Wächtershäuser & Hartz
Patentanwaltspartnerschaft mbB
Weinstraße 8
80333 München / DE
Former [2020/28]
Opponent(s)01  20.09.2018  27.09.2018  ADMISSIBLE
HGF
1 City Walk
Leeds Yorkshire LS11 9DX / GB
Opponent's representative
HGF
1 City Walk
Leeds LS11 9DX / GB
 02  20.09.2018  27.09.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Schiener, Jens
Wächtershäuser & Hartz
Patentanwaltspartnerschaft mbB
Weinstraße 8
80333 München / DE
Former [2018/44]
Opponent(s)01  20.09.2018  27.09.2018  ADMISSIBLE
HGF Limited
1 City Walk
Leeds Yorkshire LS11 9DX / GB
Opponent's representative
HGF Limited
1 City Walk
Leeds West Yorkshire LS11 9DX / GB
 02  20.09.2018  27.09.2018  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
49131 Petach Tikva / IL
Opponent's representative
Schiener, Jens
Wächtershäuser & Hartz
Patentanwaltspartnerschaft mbB
Weinstraße 8
80333 München / DE
05.10.2018Invitation to proprietor to file observations on the notice of opposition
13.02.2019Reply of patent proprietor to notice(s) of opposition
13.03.2020Cancellation of oral proceeding that was planned for 26.03.2020
26.03.2020Date of oral proceedings
20.04.2021Date of oral proceedings
27.05.2021Despatch of minutes of oral proceedings
17.04.2023Despatch of a communication from the opposition division (Time limit: M02)
17.10.2023Despatch of interlocutory decision in opposition
27.10.2023Legal effect of interlocutory decision in opposition
08.02.2024Despatch of communication that the patent will be maintained as amended
20.02.2024Fee for printing new specification paid
Appeal following opposition05.08.2021Appeal received No.  T1057/21
05.08.2021Payment of appeal fee
06.10.2021Statement of grounds filed
25.01.2023Result of appeal procedure: maintenance in amended form
16.03.2023Despatch of the decision of the Board of Appeal
27.07.2021Appeal received No.  T1057/21
27.07.2021Payment of appeal fee
06.10.2021Statement of grounds filed
25.01.2023Result of appeal procedure: maintenance in amended form
16.03.2023Despatch of the decision of the Board of Appeal
09.07.2021Appeal received No.  T1057/21
09.07.2021Payment of appeal fee
04.10.2021Statement of grounds filed
25.01.2023Result of appeal procedure: maintenance in amended form
16.03.2023Despatch of the decision of the Board of Appeal
26.01.2023Date of oral proceedings
27.01.2023Minutes of the oral proceedings despatched
Fees paidRenewal fee
13.09.2016Renewal fee patent year 03
10.03.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ20.12.2017
SM20.12.2017
GB07.03.2023
FI06.03.2024
HR06.03.2024
IE06.03.2024
LT06.03.2024
LU06.03.2024
LV06.03.2024
RO06.03.2024
RS06.03.2024
SK06.03.2024
HU07.03.2024
EE31.03.2024
MC02.04.2024
[2025/10]
Former [2025/09]CZ20.12.2017
SM20.12.2017
GB07.03.2023
FI06.03.2024
LT06.03.2024
LU06.03.2024
LV06.03.2024
RO06.03.2024
RS06.03.2024
HU07.03.2024
EE31.03.2024
MC02.04.2024
Former [2025/07]CZ20.12.2017
SM20.12.2017
GB07.03.2023
FI06.03.2024
LT06.03.2024
LU06.03.2024
LV06.03.2024
RO06.03.2024
RS06.03.2024
HU07.03.2024
MC02.04.2024
Former [2025/01]CZ20.12.2017
SM20.12.2017
GB07.03.2023
FI06.03.2024
LU06.03.2024
LV06.03.2024
RO06.03.2024
RS06.03.2024
HU07.03.2024
MC02.04.2024
Former [2024/52]CZ20.12.2017
SM20.12.2017
GB07.03.2023
FI06.03.2024
LU06.03.2024
LV06.03.2024
RO06.03.2024
RS06.03.2024
MC02.04.2024
Former [2024/49]CZ20.12.2017
SM20.12.2017
GB07.03.2023
FI06.03.2024
LV06.03.2024
RO06.03.2024
RS06.03.2024
Former [2024/48]CZ20.12.2017
SM20.12.2017
GB07.03.2023
FI06.03.2024
Former [2024/46]SM20.12.2017
GB07.03.2023
FI06.03.2024
Former [2024/09]SM20.12.2017
GB07.03.2023
Former [2018/40]SM20.12.2017
Documents cited:Search[I]WO2005097062  (NOVARTIS AG [CH], et al);
 [I]WO2007045445  (NOVARTIS AG [CH], et al);
 [A]WO2012003987  (RATIOPHARM GMBH [DE], et al)
ExaminationWO2004035026
OppositionWO2004035026
 WO2005097062
 WO2007045445
 WO2009067557
 WO2010035282
 US2011097413
 WO2012042224
 WO2010143006
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.